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ABSTRACT
Background. In patients with esophageal cancer, evidence
for prognostic signiﬁcance of preoperative quality of life
(QoL) is limited, while the prognostic signiﬁcance of
postoperative QoL has not been investigated at all.
Aim. To determine whether preoperative and postopera-
tive QoL measurements can predict survival independently
from clinical and pathological factors, in patients with
potentially curable esophageal adenocarcinoma.
Methods. A randomized controlled trial was performed
from 1994 to 2000 in two academic medical centres,
comparing transthoracic and transhiatal esophagectomy.
QoL questionnaires were sent before and 3 months after
surgery (Medical Outcome Study Short Form-20 and
Rotterdam Symptom Checklist). Uni- and multivariate Cox
regression analyses were used to examine ﬁrstly the
prognostic value of preoperative QoL and several clinical
factors, and secondly of postoperative QoL, several clinical
factors, and pathological staging.
Results. Out of 220 randomized patients, 199 participated
in the QoL-study. In the multivariate preoperative model
physical symptom scale (p = 0.021), tumor length (p =
0.034), and endosonographic T-stage (p = 0.003) were
predictive for overall survival. In the postoperative multi-
variate analysis, social functioning (p = 0.035), pain
(p = 0.026), and activity level (p = 0.037) predicted sur-
vival, besides pathological T-stage (p\0.001) and
N-stage (p\0.001).
Conclusion. In the present paper the ﬁrst large consecu-
tive series of potentially curable esophageal cancer patients
is presented in whom prospectively collected QoL data
before and after potentially curative surgical resection were
used to predict survival. Both preoperative (physical
symptoms) and postoperative (social functioning, pain, and
activity level) QoL subscales are independent predictors of
survival in potentially curable patients with esophageal
adenocarcinoma.
Surgeryisconsideredtobethe best curative treatmentfor
patients with advanced esophageal cancer, whether or not
preceded by neoadjuvant therapy.
1 Despite many improve-
ments in oncological treatment and perioperative care,
survival remains poor.
2 Even after potentially curative
esophagectomy 5-year survival rates rarely exceed 40%.
3–5
Long-term survival depends on several factors including
well-known clinical and pathological parameters.
6 Predic-
tion of long-term survival is of great importance because a
major proportion of patients want a realistic and individu-
alized approach from the cancer specialist when discussing
their prognosis.
7,8
Recently,patient-reportedoutcomeshavebeenstudiedas
prognostic factors for survival in oncological patients.
9 In
these studies pretreatment quality of life (QoL) has been
shown to be signiﬁcantly associated with survival in various
types of cancer patients, such as those with colorectal,
breast, prostate, and lung cancer.
10–13 However, for patients
with esophageal cancer, solid evidence for prognostic
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14–16 The
prognostic value of posttreatment QoL for this group of
cancer patients has not been investigated at all.
The aim of the present study is to examine to what
extent pre- and postoperative QoL subscales are able to
predict survival, independently from well-known clinical
and pathological prognostic factors, in a large homoge-
neous series of patients with potentially curable esophageal
adenocarcinoma.
PATIENTS AND METHODS
Patients
Eligible patients with histologically conﬁrmed adeno-
carcinoma of the distal esophagus or gastric cardia
substantially involving the distal esophagus without evi-
dence of distant dissemination and/or local irresectability
were randomly assigned to undergo transhiatal esopha-
gectomy or transthoracic esophagectomy with extended en
bloc lymphadenectomy. Patients were included between
April 1994 and February 2000, in two academic medical
centres. The study was approved by the medical ethics
committees. Patients were older than 18 years and in
adequate condition as indicated by their assignment to
American Society of Anesthesiologists (ASA) class I or
II.
17 Exclusion criteria were previous or coexisting cancer,
neoadjuvant chemotherapy or radiation therapy, recurrent
laryngeal nerve palsy, and the impossibility to construct a
gastric tube. Details of design, surgical technique, and
clinical results of this trial have been reported earlier.
4,18
Summarizing the most important results of this trial,
transhiatal esophagectomy proved to be associated with
lower morbidity than transthoracic esophagectomy with
extended en bloc lymphadenectomy. There was no signif-
icant overall survival beneﬁt for either approach, but
compared with limited transhiatal resection, extended
transthoracic esophagectomy for type I esophageal adeno-
carcinoma showed an ongoing trend towards better 5-year
survival. Moreover, patients with a limited number of
positive lymph nodes in the resection specimen seemed to
beneﬁt from an extended transthoracic esophagectomy.
Clinical data was collected prospectively.
Quality-of-Life Measurement
QoL data were gathered by using self-administered QoL
questionnaires, which were sent to the patients before and
3 months after surgery. If the patient did not return the
questionnaire, he or she received one reminder.
Generic QoL was measured with the Medical Outcome
Study Short Form-20 (MOS SF-20), a reliable and valid
standardized measure containing 20 items measuring
health perceptions, physical functioning, role functioning,
social functioning, mental health, energy, and bodily
pain.
19 The MOS SF-20 was scored on a ﬁve-point scale.
All raw scales were linearly converted to a 0–100 scale,
with higher scores indicating better QoL, except for bodily
pain where a higher score indicated more pain.
Disease-speciﬁc QoL was measured by the Rotterdam
Symptom Checklist (RSCL), an extensively validated
self-report questionnaire designed for use with cancer
patients.
20,21 We adapted the original RSCL by adding nine
physical symptoms speciﬁc to esophageal carcinoma
(dysphagia, loss of taste, weight loss, early satiety, blown-
up feeling, hoarseness, pain behind chest bone, food not
going down, and nocturnal coughing) and omitting seven
less relevant physical items (burning eyes, dry mouth, hair
loss, shivering, tingling hands or feet, painful muscles, and
lower back pain).
22 The adapted RSCL contained 41
items, covering 25 physical symptom items, 7 psycholog-
ical symptom items, 8 items on activity level, and 1 item
measuring global QoL. Answers were rated on a four-point
response scale, except for the global QoL item, which was
assessed on a seven-point scale. All raw scales were line-
arly converted to a 0–100 scale, with higher scores
indicating better QoL.
Follow-Up
All patients were seen at the outpatient clinic at intervals
of 3–4 months during the ﬁrst 2 years and every 6 months
for 3 more years. After 5 years, follow-up data were
obtained by telephone from the patients or his or her family
practitioner. The last check on follow-up of all patients was
performed in February 2005. Recurrence of disease was
diagnosed on clinical grounds. However, whenever a
relapse was suspected, radiologic, endoscopic or histologic
conﬁrmation was sought.
Statistical Analysis
Survival times were calculated from time of randomi-
zation to time of death from any cause or time to last
follow-up visit (at which time data were censored). Dis-
ease-free survival was counted up to time of ﬁrst relapse
and patients were censored at time of their last visit or
when they died of non-disease-related causes without
previous relapse. Survival curves were constructed by the
Kaplan–Meier method.
In the ﬁrst part of the statistical analysis, univariate Cox
regression analysis was performed using all preoperative
QoL subscales and several well-known preoperative clini-
cal factors including age, sex, tumor length, weight loss,
and endosonographic tumor–node–metastasis (TNM) stage
24 M. van Heijl et al.(uTNM). All variables with p\0.05 were included in
multivariate analysis. Using backward elimination a ﬁnal
multivariate model was created keeping only variables with
p\0.05. In case there was the problem of monotone
likelihood because of zero events in any of the strata of the
predictors, Cox regression analysis with Firth penalization
was used.
23 Cox regression analysis was performed for
overall and disease-free survival. Since pathological stage
is not available preoperatively, we included only clinical
factors actually available preoperatively in this part of the
analysis.
The second part of the analysis was performed in the
same manner, now using the postoperative QoL subscales,
and pathological TNM stage of the resection specimen
instead of endosonographical TNM stage. We deliberately
chose not to analyze all QoL items separately and only to
use subscales, to reduce chance-related ﬁndings. Statistical
analysis was performed with the Statistical Package for the
Social Sciences software version 15.0 (SPSS, Chicago, IL).
RESULTS
Between April 1994 and February 2000, 220 patients
were randomized for transhiatal or transthoracic esopha-
gectomy. A total of 199 patients agreed to participate in the
QoL study. Fourteen patients were enrolled into the study
before the quality-of-life substudy had started, and seven
patients were not sent baseline questionnaires because of
an administrative error. Patient characteristics are sum-
marized in Table 1. Preoperative QoL-questionnaires were
returned by 187 patients (94.0%). The QoL questionnaires
sent 3 months postoperatively were returned by 178 of the
199 participating patients (89.4%); the remaining 9 patients
(4.5%) deceased within 3 months of surgery.
In all patients, the operation was performed at least
5 years earlier, ensuring a minimal potential follow-up of
5 years (range 5–10.6 years). Overall 5-year survival was
35.5% and 5-year disease-free survival was 32.6% (Fig. 1a,
b).
All of the median QoL subscale scores decreased or
remained unchanged after surgery, except for RSCL psy-
chological symptoms (Table 2).
On univariate Cox regression analysis of preoperative
QoL scores only RSCL physical symptoms [hazard ratio
(HR) 0.654; p = 0.010]and RSCLactivitylevel (HR 0.710;
p = 0.033) proved signiﬁcantly predictive for overall sur-
vival (Table 3). Weight loss (HR 1.037; p = 0.004), tumor
TABLE 1 Clinicopathological characteristics of patients undergoing
potentially curative esophagectomy
All patients (n = 199)
Age in years (median) [range] 64 [35–78]
Sex (male/female) 173/26
Tumor length in cm (median) [range] 4 [1–12]
Weight loss (kg) [range] 4 [–7 to 27]
Transhiatal versus transthoracic 93 (47%)/106 (53%)
Pathological T-stage
T1 35 (17.6%)
T2 23 (11.6%)
T3 141 (70.9)
T4 0 (0%)
Pathological N-stage
N0 55 (27.6%)
N1 144 (72.4%)
Returned preoperative questionnaire 187 (94.0%)
Returned postoperative questionnaire 178 (89.4%)
1.0
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0.2
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FIG. 1 a Overall survival of all patients undergoing potentially curative esophagectomy. b Disease-free survival of all patients undergoing
potentially curative esophagectomy
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(T1 versus T3 HR 0.035; p = 0.001 and T2 versus T3 HR
0.805; p = 0.333) were the clinical factors predictive for
overall survival in univariate analysis. Endosonographic N-
stage (HR 1.155; p = 0.263) appeared not to be a predictive
factor for overall survival. After backward elimination,
RSCL physical symptoms (HR 0.668; p = 0.021), tumor
length (HR 1.082; p = 0.034), and endosonographic T-
stage (T1 versus T3 HR 0.050; p = 0.003 and T2 versus T3
HR 0.912; p = 0.717) remained independent prognostic
factorsin the ﬁnal multivariateCox regressionmodelfor the
preoperative situation (Table 4).
Univariate analysis of the postoperative QoL subscale
scores revealed many signiﬁcant predictors for overall
survival: SF20 health perception (HR 0.835; p = 0.027),
SF20 social functioning (HR 0.887; p = 0.011), SF20
energy (HR 0.785; p = 0.006), SF20 pain (HR 1.196;
p = 0.006), SF20 mental health (HR 0.818; p = 0.030),
RSCL physical symptoms (HR 0.724; p = 0.017), RSCL
activity level (HR 0.710; p\0.001), and RSCL global
quality of life (HR 0.770; p = 0.004). Weight loss (HR
1.033; p = 0.019) and tumor length (HR 1.138; p\0.001)
were again clinical predictors for overall survival on uni-
variate analysis. Pathological T-stage (T1 versus T3 HR
0.084; p\0.001 and T2 versus T3 HR 0.487; p = 0.014)
and pathological N-stage (HR 4.617; p\0.001) were also
signiﬁcantly predictive for overall survival.
After backward elimination, the ﬁnal multivariate Cox
regression model for postoperative parameters showed
SF20 social functioning (HR 0.835; p = 0.035), SF20 pain
(HR 1.196; p = 0.026), RSCL activity level (HR 0.785;
p = 0.037), pathological T-stage (T1 versus T3 HR 0.122;
p\0.001 and T2 versus T3 HR 0.430; p = 0.009), and
pathological N-stage (HR 3.433; p\0.001) as indepen-
dent predictors for overall survival.
Preoperative univariate Cox regression analysis of risk
factors for disease-free survival showed again that RSCL
physical symptoms (HR 0.641; p = 0.012), RSCL activity
level (HR 0.695; p = 0.038), weight loss (HR 1.044;
p = 0.001), tumor length (HR 1.159; p\0.001), and en-
dosonographic T-stage (T1 versus T3 HR 0.020; p\0.001
and T2 versus T3 HR 0.868; p = 0.540) were signiﬁcant
predictors (Table 3). After backward elimination only
RSCL physical symptoms (HR 0.641; p = 0.024), tumor
length (HR 1.112; p = 0.008), and endosonographic
T-stage (T1 versus T3 HR 0.029; p\0.001 and T2 versus
T3 HR 0.975; p = 0.918) were signiﬁcant predictors in the
multivariate model for disease-free survival (Table 4).
Postoperative univariate Cox regression analysis for
disease-free survival showed the same range of QoL sub-
scales to be signiﬁcantly predictive as in the univariate
analysis for overall survival, except that SF-20 physical
functioning was a signiﬁcant predictor in the disease-free
analysis and SF-20 social functioning was not (Table 3).
After backward elimination a multivariate model was
created including only signiﬁcant predictors for disease-
free survival: SF-20 pain (HR 1.321; p = 0.001), RSCL
activity level (HR 0.724; p\0.001), pathological T-stage
(T1 versus T3 HR 0.124; 0 = 0.001 and T2 versus T3 HR
0.463; p = 0.029), and pathological N-stage (HR 3.385;
p = 0.001).
DISCUSSION
In the present paper the ﬁrst large consecutive series of
potentially curable esophageal cancer patients is presented
in whom prospectively collected QoL data before and after
potentially curative surgical resection were used to predict
survival. In the preoperative setting only the physical
symptom scale was an independent predictor of overall
survival, besides the well-known tumor length and en-
dosonographic T-stage.
6,24 In the postoperative setting the
social functioning scale, the pain scale, and the activity
level predicted overall survival independently, besides
pathological T-stage and N-stage. Analysis for disease-free
survival in the postoperative setting showed the pain scale
and activity level to be even stronger predictors compared
with overall survival.
QoL subscales that were found to predict survival were
different preoperatively (physical symptoms) compared
with postoperatively (social functioning, pain, and activity
level). It might be hypothesized that the predictive strength
of preoperative QoL is dominated by the physical symptom
subscale, because it probably reﬂects tumor stage. Perhaps,
TABLE 2 Pre- and postoperative quality of life scores (median and
interquartile range) in patients undergoing potentially curative
esophagectomy
Preoperative
QoL
(N = 187)
QoL score 3 months
after surgery
(N = 178)
SF-20 physical functioning 83 [50–100] 42 [26–67]
SF-20 health perception 50 [35–70] 42 [32–65]
SF-20 social functioning 100 [60–100] 74 [46–100]
SF-20 energy 72 [60–85] 55 [40–75]
SF-20 pain 25 [0–50] 25 [0–50]
SF-20 role functioning 100 [50–100] 38 [0–100]
SF-20 mental health 76 [64–88] 76 [60–92]
RSCL physical symptoms 84 [80–92] 77 [69–85]
RSCL activity level 100 [93–100] 92 [76–100]
RSCL psychological symptoms 76 [62–90] 81 [71–95]
RSCL global quality of life 67 [50–83] 67 [50–83]
SF-20 medical outcomes study short form, RSCL Rotterdam symptom
checklist
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Quality of Life Predicts Survival in Esophageal Cancer 27TABLE 4 Multivariate backward elimination Cox regression model of pre- and postoperative risk factors for overall and disease-free survival
in patients undergoing potentially curative esophagectomy
QoL Overall survival Disease-free survival
Preoperative QoL
(N = 187)
QoL 3 months after surgery
(N = 178)
Preoperative QoL
(N = 187)
QoL 3 months after surgery
(N = 178)
HR
a (95% CI) P value HR
a (95% CI) P value HR
b (95% CI) P value HR
b (95% CI) P value
SF-20 physical
functioning
Not in model Not in model Not in model Not in model
SF-20 health
perception
Not in model Not in model not in model Not in model
SF-20 social
functioning
Not in model 0.835
(0.710–0.980)
0.035 Not in model Not in model
SF-20 energy Not in model Not in model Not in model Not in model
SF-20 pain Not in model 1.196
(1.020–1.401)
0.026 Not in model 1.321
(1.006–1.022)
0.001
SF-20 role
functioning
Not in model Not in model Not in model Not in model
SF-20 mental
health
Not in model Not in model Not in model Not in model
RSCL physical
symptoms
0.668
(0.470–0.942)
0.021 Not in model 0.641
(0.442–0.942)
0.024 Not in model
RSCL activity
level
Not in model 0.785
(0.641–0.980)
0.037 Not in model 0.724
(0.975–0.992)
\0.001
RSCL
psychological
symptoms
Not in model Not in model Not in model Not in model
RSCL global
quality of life
Not in model Not in model Not in model Not in model
Clinical
Age [years] Not in model Not in model Not in model Not in model
Sex (male/female) Not in model Not in model Not in model Not in model
Weight loss [kg] Not in model Not in model Not in model Not in model
Tumor length [cm] 1.082
(1.006–1.164)
0.034 Not in model 1.112
(1.029–1.198)
0.008 Not in model
uT-stage
T1 vs. T3 0.050
(0.007–0.361)
0.003 NA 0.029
(0.0002–0.207)
\0.001 NA
T2 vs. T3 0.912
(0.554–1.501)
0.717 NA 0.975 (0.585–1.558) 0.918 NA
uN-stage
(N1 vs. N0)
Not in model NA Not in model NA
pT-stage
T1 vs. T3 NA 0.122
(0.041–0.367)
\0.001 NA 0.124
(0.035–0.441)
0.001
T2 vs. T3 NA 0.430
(0.229–0.809)
0.009 NA 0.463
(0.232–0.922)
0.029
pN-stage
(N1 vs. N0)
NA 3.433
(1.798–6.555)
\0.001 NA 3.385
(1.640–6.986)
0.001
HR hazard ratio, CI conﬁdence interval, u ultrasonographical, p pathological, NA not applicable, SF-20 medical outcomes study short form,
RSCL Rotterdam symptom checklist
a Hazard ratio provides the likelihood of recurrent disease for a patient with a score of 20 points more than another patient
b Hazard ratio provides the likelihood of recurrent disease for a patient with a score of 20 points more than another patient
All variables with a p-value\0.05 were made bold
28 M. van Heijl et al.a more aggressive and extensive tumor would result in a
lower score on this speciﬁc subscale and therefore in worse
survival. Postoperative QoL subscales predicting survival
seemed to be more related to the recovery from the
immobilizing and painful effects of major surgery (social
functioning, pain, and activity level). However, it remains
unclear whether these surgery-related effects fully account
for the prognostic signiﬁcance of these speciﬁc subscales.
In addition to intrinsic differences in pre- and postop-
erative QoL measurements, clinical applicability would
also be quite different. Preoperative QoL measurements
have signiﬁcant additional value in disclosing individual
prognosis. Using our multivariate prediction model, it
might even be possible to help patients making treatment-
related decisions. By adding the predictive QoL subscales
to conventional staging modalities, a more realistic prog-
nosis can be disclosed, which ensures patients to make
well-considered choices.
Postoperative predictive QoL subscales, in combination
with pathological tumor stage, can help to reassess indi-
vidual prognosis. Our data indicate that, in patients who
explicitly want to be informed about their prognosis, lon-
gitudinal QoL measurements can be useful. The fact that the
pain subscale and activity level are such strong predictors
for disease-free survival suggests that in the future these
measurements might even be used as surveillance modality
forrecurrentdisease;alowscoreonthesesubscalescouldbe
an indication for further diagnostic imaging.
Few studies have investigated the prognostic value of
pretreatment QoL in patients with esophageal cancer.
14–16
Data from the three available studies support the view that
a lower pretreatment score on some of the QoL subscales
negatively affects survival, but all three studies consisted of
heterogeneous patient populations with both potentially
curable and incurable patients. Predictive value of post-
treatment QoL subscales has not previously been
investigated at all for this group of patients. One study
examined the change between baseline QoL subscales and
posttreatment QoL subscales, albeit in a relatively small
series of patients (n = 38).
14
The ﬁrst study by Blazeby et al. investigating prognostic
value of QoL for patients with esophageal cancer included
89 patients with disease stage II–IV and used European
Organisation for Research and Treatment of Cancer (EO-
RTC) QLQ-C30 and EORTC OES24 QoL questionnaires.
14
Potentially curative esophagectomy was performed in 55 of
the patients; no subgroup analysis was performed using only
these patients. The authors found that better pretreatment
physical function was associated with longer survival. This
corresponds with our results indicating preoperative physi-
cal symptoms to be predictive for survival. In that same
study the change in emotional function between baseline
QoL and the measurement 6 months after treatment was
also reported to be signiﬁcantly predictive for survival, even
in a relatively small subgroup of patients (n = 38). Corre-
sponding postoperative QoL subscales in the present study
(e.g., mental and/or psychological function) did not prove to
be independently predictive for survival.
In a study by Chau et al., including over 1,000 mainly
metastatic esophageal cancer patients the EORTC QLQ-
C30 questionnaire was used to assess the prognostic value
of pretreatment QoL.
15 Physical function, role function,
and global quality of life were found to be independent
predictors for survival. Unfortunately, the QoL subscales
were only analyzed separately in different multivariate
models, each including several clinical factors and one
QoL subscale, therefore the possible interrelationship
between the QoL subscales remains unclear.
A recently published paper investigating QoL as a pre-
dictor for survival, also using the EORTC QLQ-C30, found
only preoperative appetite loss to be an independent
prognostic factor in patients with gastroesophageal can-
cer.
16 Appetite loss is one of the 23 items of which our
RSCL physical function subscale is composed. We delib-
erately chose not to analyze all QoL items separately and
only to use subscales, to reduce chance-related ﬁndings.
In the present study, a fairly homogeneous patient
population of potentially curable patients with esophageal
cancer was used. This is in contrast to previous studies
consisting of rather heterogeneous patient populations also
including locally advanced (T4) and metastatic (M1)
tumors.
14–16 Heterogeneity leads to less precise results for
individual prognosis. The restrictive selection criteria that
were applied in our study, however, limit its generaliz-
ability. Another potential limitation of the present study is
that we did not assess the more recently discovered
(pathological) predictors, such as extracapsular lymph node
involvement.
25 Furthermore, it is generally accepted to
include approximately one variable in multivariate logistic
regression analysis for every ten events in the patient
population. Therefore, the total number of variables
that can be tested is limited. Nevertheless, we did assess the
inﬂuence of the main comparison of the original random-
ized trial: although some QoL variables differed
signiﬁcantly 3 months after surgery between the transhiatal
and the transthoracic group, including surgical approach as
a variable in the multivariate analysis did not inﬂuence the
prognostic signiﬁcance of QoL and other variables.
22
Remarkably, endosonographic N-stage was not a sig-
niﬁcant predictor for survival in our study, not even on
univariate analysis. This is in contrast with previous
reports.
24,26
Most studies investigating preoperative prognostication
using QoL also include pathological TNM stage in the
multivariate Cox regression models.
14–16 Since pathologi-
cal stage is not available preoperatively, we used a more
Quality of Life Predicts Survival in Esophageal Cancer 29realistic approach, including only clinical factors actually
available preoperatively.
In conclusion, the results of the present study support
the application of predictive QoL subscales in daily clinical
practice before and after surgery.
Current guidelines on diagnosis and treatment of esoph-
ageal cancer do not recommend any form of postoperative
monitoring, while patient preference for disclosure of an
individual prognosis is still prominent postoperatively.
8
Therefore, postoperative predictive QoL subscales com-
bined with pathological TNM stage could be a useful,
noninvasive approach to update and improve individual
prognosis.
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